MX2021006209A - Montelukast para el tratamiento de la osteoartritis erosiva de la mano. - Google Patents
Montelukast para el tratamiento de la osteoartritis erosiva de la mano.Info
- Publication number
- MX2021006209A MX2021006209A MX2021006209A MX2021006209A MX2021006209A MX 2021006209 A MX2021006209 A MX 2021006209A MX 2021006209 A MX2021006209 A MX 2021006209A MX 2021006209 A MX2021006209 A MX 2021006209A MX 2021006209 A MX2021006209 A MX 2021006209A
- Authority
- MX
- Mexico
- Prior art keywords
- montelukast
- treatment
- hand osteoarthritis
- erosive
- erosive hand
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382851 | 2018-11-26 | ||
| PCT/EP2019/082425 WO2020109230A1 (en) | 2018-11-26 | 2019-11-25 | Montelukast for the treatment of erosive hand osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006209A true MX2021006209A (es) | 2021-08-11 |
Family
ID=64665075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006209A MX2021006209A (es) | 2018-11-26 | 2019-11-25 | Montelukast para el tratamiento de la osteoartritis erosiva de la mano. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12539296B2 (enExample) |
| EP (1) | EP3886857B1 (enExample) |
| JP (1) | JP7399502B2 (enExample) |
| CN (1) | CN113347975B (enExample) |
| AU (1) | AU2019386235B2 (enExample) |
| BR (1) | BR112021009980A2 (enExample) |
| CA (1) | CA3120920C (enExample) |
| DK (1) | DK3886857T3 (enExample) |
| ES (1) | ES2961390T3 (enExample) |
| FI (1) | FI3886857T3 (enExample) |
| HR (1) | HRP20231283T1 (enExample) |
| HU (1) | HUE063579T2 (enExample) |
| MA (1) | MA54276B1 (enExample) |
| MD (1) | MD3886857T2 (enExample) |
| MX (1) | MX2021006209A (enExample) |
| MY (1) | MY203365A (enExample) |
| PL (1) | PL3886857T3 (enExample) |
| PT (1) | PT3886857T (enExample) |
| RS (1) | RS64668B1 (enExample) |
| SI (1) | SI3886857T1 (enExample) |
| TW (1) | TWI850283B (enExample) |
| WO (1) | WO2020109230A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4228641A1 (en) * | 2020-10-13 | 2023-08-23 | Diomed Developments Limited | Gel formulations comprising montelukast |
| GB2599912B (en) * | 2020-10-13 | 2023-04-19 | Diomed Dev Ltd | New formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201020085D0 (en) * | 2010-11-26 | 2011-01-12 | Xaragen Pharma Ltd | Methods and reagents for the treatment of arthritic disorders |
| CA2931978A1 (en) | 2013-12-02 | 2015-06-11 | Abbvie Inc. | Compositions and methods for treating osteoarthritis |
-
2019
- 2019-11-25 MD MDE20210946T patent/MD3886857T2/ro unknown
- 2019-11-25 DK DK19805716.8T patent/DK3886857T3/da active
- 2019-11-25 FI FIEP19805716.8T patent/FI3886857T3/fi active
- 2019-11-25 PL PL19805716.8T patent/PL3886857T3/pl unknown
- 2019-11-25 ES ES19805716T patent/ES2961390T3/es active Active
- 2019-11-25 RS RS20230911A patent/RS64668B1/sr unknown
- 2019-11-25 EP EP19805716.8A patent/EP3886857B1/en active Active
- 2019-11-25 HU HUE19805716A patent/HUE063579T2/hu unknown
- 2019-11-25 AU AU2019386235A patent/AU2019386235B2/en active Active
- 2019-11-25 US US17/296,703 patent/US12539296B2/en active Active
- 2019-11-25 CN CN201980089991.6A patent/CN113347975B/zh active Active
- 2019-11-25 MA MA54276A patent/MA54276B1/fr unknown
- 2019-11-25 BR BR112021009980-8A patent/BR112021009980A2/pt unknown
- 2019-11-25 WO PCT/EP2019/082425 patent/WO2020109230A1/en not_active Ceased
- 2019-11-25 SI SI201930635T patent/SI3886857T1/sl unknown
- 2019-11-25 MY MYPI2021002897A patent/MY203365A/en unknown
- 2019-11-25 HR HRP20231283TT patent/HRP20231283T1/hr unknown
- 2019-11-25 CA CA3120920A patent/CA3120920C/en active Active
- 2019-11-25 MX MX2021006209A patent/MX2021006209A/es unknown
- 2019-11-25 PT PT198057168T patent/PT3886857T/pt unknown
- 2019-11-25 JP JP2021529734A patent/JP7399502B2/ja active Active
- 2019-11-26 TW TW108142961A patent/TWI850283B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| SI3886857T1 (sl) | 2023-12-29 |
| PT3886857T (pt) | 2023-10-25 |
| HUE063579T2 (hu) | 2024-01-28 |
| RS64668B1 (sr) | 2023-11-30 |
| AU2019386235B2 (en) | 2024-11-21 |
| JP2022508236A (ja) | 2022-01-19 |
| TWI850283B (zh) | 2024-08-01 |
| US20220047570A1 (en) | 2022-02-17 |
| FI3886857T3 (fi) | 2023-10-20 |
| EP3886857A1 (en) | 2021-10-06 |
| CA3120920A1 (en) | 2020-06-04 |
| JP7399502B2 (ja) | 2023-12-18 |
| MD3886857T2 (ro) | 2023-12-31 |
| PL3886857T3 (pl) | 2024-01-15 |
| CN113347975B (zh) | 2024-08-30 |
| AU2019386235A1 (en) | 2021-07-01 |
| CA3120920C (en) | 2024-01-02 |
| DK3886857T3 (da) | 2023-10-09 |
| ES2961390T3 (es) | 2024-03-11 |
| WO2020109230A1 (en) | 2020-06-04 |
| US12539296B2 (en) | 2026-02-03 |
| EP3886857B1 (en) | 2023-07-26 |
| BR112021009980A2 (pt) | 2021-08-17 |
| HRP20231283T1 (hr) | 2024-02-02 |
| MY203365A (en) | 2024-06-26 |
| MA54276B1 (fr) | 2023-11-30 |
| TW202038954A (zh) | 2020-11-01 |
| CN113347975A (zh) | 2021-09-03 |
| MA54276A (fr) | 2021-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2021002321A (es) | Nuevos metodos. | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| PH12015502351A1 (en) | Herbal compositions for treating pain and skin disorders | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| MY203365A (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| EP4461362A3 (en) | Nk1-antagonist combination and method for treating synucleinopathies | |
| WO2020025657A9 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
| SG10201809280PA (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| ZA202200330B (en) | Pharmaceutical composition of imatinib | |
| EA201991119A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения |